

Patent Attorney's Docket No. <u>033285-010</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Pa	tent Ap	plication of)				
Istvan SZELENYI et al.				Group Art Unit: Unassigned			
Application No.: 10/089,449) }	Examiner: Unassigned			
Int'l. Filing Date: September 26, 2000)	Confirmation No.: 9422			
	NOVEL COMBINATION OF LOTEPREDNOL AND β_2 -ADRENOCEPTOR AGONISTS						
		INFORMATION DIS TRANSMI					
		missioner for Patents o.C. 20231					
Sir:							
		ed is an Information Disclosure S d patent application.	Stateme	nt and accompanying form PTO-1449 for the			
	[X]	No additional fee for submission	n of an	IDS is required.			
ı	[]	The fee of \$180.00 (126) as set	forth in	37 C.F.R. § 1.17(p) is also enclosed.			
	[]	A certification under 37 C.F.R.	. § 1.97	(e) is also enclosed.			
!	[]	A certification under 37 C.F.R. in 37 C.F.R. § 1.17(p) are also	-	(e), and the fee of \$180.00 (126) as set forthed.			
	[]	Charge \$to Depo	osit Acc	ount No. 02-4800 for the fee due.			
	[]	A check in the amount of \$		is enclosed for the fee due.			
§§ 1.16,	, 1.17 a		this paubmittee	rge any appropriate fees under 37 C.F.R. per, and to credit any overpayment, to in duplicate.			
P.O. Bo Alexand (703) 83	Iria, Vi	rginia 22313-1404	Ву:	Peresa Stanek Rea Registration No. 30,427			

Date: June 28, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Patent Application of)
stvan SZELENYI et al.) Group Art Unit: Unassigned
Application No.: 10/889,449) Examiner: Unassigned
Int'l. Filing Date: September 26, 2000) Confirmation No.: 9422
For: NOVEL COMBINATION OF LOTEPREDNOL AND β_2 -ADRENOCEPTOR AGONISTS)))
)

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submits the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore no fee or statement is required under 37 C.F.R. § 1.97(b).

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE SWECKER & MATHIS, L.L.P.

By:

Teresa Stanek Rea Registration No. 30,427

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: June 28, 2002

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.	APPLICATION NO.			
033285-010	10/089,449			
APPLICANT				
Istvan SZELENYI et al.				
INT'L. FILING DATE	GROUP			
September 26, 2000	Unassigned			

			U.S. PATENT DOCU	IMENTS							
	U.S. Patent [Document									
Examiner	Nhambar	Kind Code	Name of Patentee or Applicant			Date of Publication					
Initials	Number	(if known)	of Cited D	ocument		(MM-DD-YY	<u> </u>				
	 										
											
		<u> </u>									
					Z 25		V 29	A 1 1 2 A			
		FO	REIGN PATENT DO	CUMENTS							
	Foreign Patent				_						
Examiner Initials	Number (if known)		Country		Date of Publication (MM-DD-YYYY)		Yes	lation no			
							(
							<u> </u>				
			<u> </u>								
77.500	W. 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 . 100 .										
		NON P	ATENT LITERATURE	DOCUMEN	ITS			4			
Funnina			(in CAPITAL LETTERS),								
Examiner Initials	item (book	, magazine, jourr	nal, serial, symposium, ca publisher, city and/or co				er(s),				
	S. Nobel, et al., "Lo Evaluation, October		nate, Clinical Potential in 339 /	the Manageme	ent of O	cular Inflammation", Ac	is Drug				
	M. Palmqvist, et al., "Late asthmatic reaction decreased after pretreatment with salbutamol and formoterol, a new long-acting beta 2-agonist", Medline (R), 1992										
	S.P. Clissold, et al., "Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in										
<u></u>	R.J. Shaw, "Pharmacology of fluticasone propionate", Medline (R), 1994										
	P.J. Barnes, et al., "Efficacy and safety of inhaled corticosteroids. New developments", Medline (R), 1998, Part A										
	<u> </u>										
Examiner Signature				Date Considered				_			